Using measurements of neutralizing antibodies: the challenge of IFN‐β therapy
- 25 July 2007
- journal article
- review article
- Published by Wiley in European Journal of Neurology
- Vol. 14 (8) , 850-859
Abstract
Although the occurrence of neutralizing antibodies (NAbs) to interferon (IFN)-beta has been acknowledged since the pivotal trials of IFN-beta in multiple sclerosis (MS), the effect of these antibodies has for several reasons been debated. The main reason for the controversies has been insufficient knowledge of the fact that clinically relevant NAbs do not appear until 12-18 months after initiation of IFN-beta therapy which make studies of 2 years or less unsuited to assess the clinical relevance of NAbs. Further, changes in NAb affinity occur and contribute to increase NAb effects by time. The present paper reviews our current knowledge of NAbs and stresses the importance of using measurements of NAbs routinely. It is concluded that NAb titres are important for the biological response to IFN-beta. Patients with low or intermediate titres may have preserved a full or partial biological response and might still benefit from IFN-beta therapy. However, persistent high titres of NAbs indicate an abrogation of the biological response and, hence, absence of therapeutic efficacy, and this observation should lead to a change of therapy. The application of the existing information about NAbs in clinical practice would lead to improved efficacy of IFN-beta treatment for the benefit of patients with MS.Keywords
This publication has 63 references indexed in Scilit:
- Immunogenicity and tolerability of an investigational formulation of interferon-β1a: 24- and 48-week interim analyses of a 2-year, single-arm, historically controlled, phase IIIb study in adults with multiple sclerosisClinical Therapeutics, 2007
- Qualitative and quantitative analysis of antibody response against IFNβ in patients with multiple sclerosisMultiple Sclerosis Journal, 2006
- Clinical link between MHC class II haplotype and interferon-beta (IFN-β) immunogenicityClinical Immunology, 2006
- The importance of measuring IFNβ bioactivity: Monitoring in MS patients and the effect of anti-IFNβ antibodiesJournal of Neuroimmunology, 2005
- Comparisons of Visual Properties between Tectal and Thalamic Neurons with Overlapping Receptive Fields in the PigeonBrain, Behavior and Evolution, 2004
- Mini ReviewHuman Interferons Alpha, Beta and OmegaGrowth Factors, 2004
- Interspecific Allometry of the Brain and Brain Regions in Parrots (Psittaciformes): Comparisons with Other Birds and PrimatesBrain, Behavior and Evolution, 2004
- Bioequivalence and the immunogenicity of biopharmaceuticalsNature Reviews Drug Discovery, 2002
- Combination of cyclophosphamide and interferon-beta halts progression in patients with rapidly transitional multiple sclerosisJournal of Neurology, Neurosurgery & Psychiatry, 2001
- The Neutralization of Interferons by Antibody. I. Quantitative and Theoretical Analyses of the Neutralization Reaction in Different Bioassay SystemsJournal of Interferon & Cytokine Research, 2001